MY008211A

盐酸兰诺可泮

Report date: 2026/03/04 20:01:44
NME

Base Information

Drug NameMY008211A
Drug Alias NameMY008211A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionComplement factor B inhibitors
TargetsComplement factor B
Therapy Area/IndicationsHemoglobinuria, ParoxysmalNephrosisLupus Nephritis +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaNDA/BLA
Originator CompaniesShanghai Meiyue Biotechnology Dev Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesShanghai Meiyue Biotechnology Dev Co LtdWuhan Qr Pharmaceuticals Co LtdWuhan Createrna Science and Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsHemoglobinuria, ParoxysmalNephrosisLupus Nephritis +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A